Multivariate analysis of OS in ICI regimens by Cox proportional hazard model
| Covariate | HR (95% CI) | P value | |
| HIC (vs HIC-cold) | HIC-hot | 0.37 (0.25 to 0.53) | <0.0001 |
| ECOG (vs PS 0) | PS 1 | 1.47 (0.89 to 2.42) | 0.133 |
| PS 2+ | 2.64 (1.53 to 4.54) | <0.001 | |
| Age (vs <65 years) | ≥65 years | 1.52 (1.07 to 2.15) | 0.019 |
| Histology (vs adenocarcinoma) | Squamous cell | 1.45 (0.87 to 2.39) | 0.151 |
| NSCLC other | 0.54 (0.30 to 0.99) | 0.045 | |
| Therapy (vs ICI+ chemotherapy) | ICI monotherapy | 1.67 (1.11 to 2.51) | 0.013 |
| ICI with other | 1.94 (0.66 to 5.74) | 0.230 | |
| PD-L1 expression (vs high (≥50%)) | PD-L1 low (≥1% and <50%) | 1.54 (0.91 to 2.60) | 0.109 |
| PD-L1 negative (<1%) | 1.88 (1.07 to 3.32) | 0.028 | |
| N/A | 0.99 (0.62 to 1.61) | 0.980 | |
| Smoking history (vs never) | Ever | 1.87 (0.89 to 3.91) | 0.098 |
| Disease stage (vs IIIB) | Stage IV | 1.50 (0.72 to 3.15) | 0.281 |
| Gender (vs female) | Male | 1.02 (0.71 to 1.46) | 0.920 |
Bold indicates parameter of highest significance.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HIC, host immune classifier; HR, hazard ratio; ICI, immune checkpoint inhibition; N/A, not available; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death ligand 1 ; PS, performance status.